Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
Hepion Pharmaceuticals (NASDAQ:HEPA) announced that its Chief Medical Officer, Todd Hobbs, MD, will participate in the "Novel Targets in Oncology: Risk vs. Reward" panel at the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022. Dr. Hobbs will discuss the Phase 2 clinical trial of rencofilstat, targeted at treating hepatocellular carcinoma (HCC). Rencofilstat has shown promise in reducing liver fibrosis and HCC tumor burden, and has received Fast Track and Orphan Drug designations from the FDA for its development in treating NASH and HCC, respectively.
- None.
- None.
EDISON, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that its Chief Medical Officer, Todd Hobbs, MD, will participate in the “Novel Targets in Oncology: Risk vs. Reward” panel at the Cantor Oncology, Hematology & HemeOnc Conference on Wednesday, September 28, 2022 at 9:00 a.m. Eastern Time at the New York Palace Hotel.
During the panel alongside other industry peers, Dr. Hobbs will focus his discussion on Hepion’s upcoming Phase 2 clinical trial of rencofilstat in the treatment of HCC. Due to the format of the event, no webcast will be available.
About Hepion Pharmaceuticals
The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies. In November 2021, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for rencofilstat for the treatment of NASH. That was followed in June 2022 by the FDA’s granting of Orphan Drug designation to rencofilstat for the treatment of HCC.
Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to rencofilstat, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for rencofilstat to expand the company's footprint in the cyclophilin inhibition therapeutic space.
For further information, please contact:
Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com
FAQ
What is Hepion Pharmaceuticals' stock symbol?
When is the Cantor Oncology Conference where Hepion's CMO will speak?
What will Dr. Todd Hobbs discuss at the conference?
What designations has rencofilstat received from the FDA?
What is the purpose of Hepion's AI-POWR platform?
